Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
A Prospective, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Adaptive Phase 3 Study With Open-label Extension to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension (MACiTEPH)

The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).

macitentan
  • 85 views
  • 23 Oct, 2022
  • 108 locations
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH (RIVERII)

This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.

  • 0 views
  • 29 Apr, 2022
  • 1 location
An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial (RIALTO)

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials

pulmonary arterial hypertension
riociguat
adempas
  • 2 views
  • 24 Oct, 2022
  • 1 location
Riociguat (BAY 63-2521), a Stimulator of Soluble Guanylate Cyclase (sGC) - Cerebral Vasodilation and Headache Induction in Healthy Volunteers

This double-blind, randomized, placebo-controlled cross-over clinical trial aims to investigate the effects of riocigaut on cerebral arteries and headache inducing properties in healthy volunteers.

Accepts healthy volunteers
  • 0 views
  • 24 Oct, 2022
  • 1 location
THERAPY-HYBRID-BPA Trial

Riociguat could improve the exercise capacity and residual symptoms in patients with chronic thromboembolic pulmonary hypertension (CTEPH) even after normalization of pulmonary arterial pressure

right heart catheterization
riociguat
  • 2 views
  • 26 Jan, 2021
  • 1 location
Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

  • 0 views
  • 04 Oct, 2022
  • 1 location
Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension

balloon pulmonary angioplasty (BPA). Currently, only one drug (riociguat), targeting the NO pathway, is approved and reimbursed in Europe. Thus, riociguat monotherapy is considered as the standard-of-care

  • 0 views
  • 06 Dec, 2021
  • 1 location
Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE)

Following acute pulmonary embolism (PE), up to a third of patients develop post-PE syndrome described as having persistent breathlessness (dyspnea), impaired exercise capacity, and a reduced quality of life. The post-PE syndrome includes patients with chronic thromboembolic pulmonary hypertension (CTEPH), patients with chronic thromboembolic disease (CTED) those with an obstruction …

acute pulmonary embolism
FIO2
nitric oxide
dyspnea
  • 0 views
  • 07 Oct, 2022
  • 1 location
RiOciguAt UseRs Registry (ROAR)

, symptoms get worse. There is no cure for PAH, but several medications like endothelin receptor antagonists (ERAs), prostacyclin analogues (PCAs) and riociguat, a soluable guanylate cyclase

  • 2 views
  • 16 Oct, 2022
  • 28 locations
Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH) (JPMS-PAH)

The primary objective in this study is to collect post-marketing information on Riociguat safety.Thus, the information on adverse events (AEs) and adverse drug reactions (ADRs) that occur within

pulmonary arterial hypertension
riociguat
adempas
  • 10 views
  • 18 Oct, 2022
  • 1 location